title: CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma.
abstract: We studied the association between the expression of a subset of previously identified genes and clinical outcome in patients with head and neck cancer.
  
  
  
  We analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) the expression of 89 genes in tumor biopsies from stage III to IVa/b chemotherapy treated patients (n = 46). Two additional cohorts analyzed by RNAseq (The Cancer Genome Atlas [TCGA] project; n = 371) or immunohistochemistry (IHC; n = 73) were used to validate results.
  
  
  
  Thirty genes were associated with local-recurrence or progression-free survival. The best multi-gene decision-tree model to predict local recurrence included nuclear receptor coactivator 1 (NCOA1) and serum-amyloid A2 (SAA2) expression, whereas the best model to predict disease recurrence included creatine kinase mitochondrial 1 (CKMT1) and metal-regulatory transcription factor 1 (MTF1). Both models were associated with cancer-specific survival. Results were confirmed analyzing the RNAseq data included in the TCGA project. CKMT1 and NCOA1 were identified as independent risk factors for survival in an independent cohort analyzed by immunohistochemistry.
  
  
  
  CKMT1 and NCOA1 expression has prognostic significance in advanced-stage head and neck carcinoma. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1392-E1403, 2016.
authors.affiliation: Grup d'Oncogènesi i Antitumorals (GOA), Institut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona, Spain.|Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Pavón
authors.affiliation: Translational Molecular Oncology, IIB-Sant Pau, HSCSP, Barcelona, Spain.
authors.forename: Matilde
authors.initials: M
authors.lastname: Parreño
authors.affiliation: Grup d'Oncogènesi i Antitumorals (GOA), Institut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona, Spain.|Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Téllez-Gabriel
authors.affiliation: Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.|Department of Otorhinolaryngology, IIB-Sant Pau, HSCSP, Barcelona, Spain.
authors.forename: Xavier
authors.initials: X
authors.lastname: León
authors.affiliation: Grup d'Oncogènesi i Antitumorals (GOA), Institut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona, Spain.|Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
authors.forename: Irene
authors.initials: I
authors.lastname: Arroyo-Solera
authors.affiliation: Department of Otorhinolaryngology, IIB-Sant Pau, HSCSP, Barcelona, Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: López
authors.affiliation: Grup d'Oncogènesi i Antitumorals (GOA), Institut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona, Spain.|Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
authors.forename: Maria Virtudes
authors.initials: MV
authors.lastname: Céspedes
authors.affiliation: Grup d'Oncogènesi i Antitumorals (GOA), Institut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona, Spain.|Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
authors.forename: Isolda
authors.initials: I
authors.lastname: Casanova
authors.affiliation: Department of Pathology, Clínica Girona, Girona, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: Gallardo
authors.affiliation: Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.|Department of Medical Oncology, IIB-Sant Pau, HSCSP, Barcelona, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: López-Pousa
authors.affiliation: Department of Pharmacy, IIB-Sant Pau, HSCSP, Barcelona, Spain.
authors.forename: Maria Antonia
authors.initials: MA
authors.lastname: Mangues
authors.affiliation: Department of Otorhinolaryngology, IIB-Sant Pau, HSCSP, Barcelona, Spain.
authors.forename: Miquel
authors.initials: M
authors.lastname: Quer
authors.affiliation: Department of Medical Oncology, IIB-Sant Pau, HSCSP, Barcelona, Spain.
authors.forename: Agustí
authors.initials: A
authors.lastname: Barnadas
authors.affiliation: Grup d'Oncogènesi i Antitumorals (GOA), Institut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona, Spain.|Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
authors.forename: Ramón
authors.initials: R
authors.lastname: Mangues
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000235:genetics; D003402:Creatine Kinase / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000175:diagnosis* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D056920:Nuclear Receptor Coactivator 1 / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors
chemical_list: C538859:NCOA1 protein, human; D056920:Nuclear Receptor Coactivator 1; C519581:CKMT1A protein, human; D003402:Creatine Kinase
keywords: advanced-stage; biomarker; creatine kinase mitochondrial 1 (CKMT1); head and neck carcinoma; metal-regulatory transcription factor 1 (MTF1); nuclear receptor coactivator 1 (NCOA1); serum-amyloid A2 (SAA2); survival